Heyholder
‹ Activism Filings

HYUNDAI BIOSCIENCE CO., LTD. Periodic Report


AI summary · Not investment advice

Hyundai Bio sold KRW 0.5 billion in Q3 and lost KRW 5.2 billion from its main business, with sales down 16.5% from a year earlier.

Operating profit · 3 months

KRW -5.2 billion

Key facts

Revenue (3 months)
KRW 461.8 million
Net income (3 months)
KRW -6.8 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 553.1 million
Revenue (year to date)
KRW 1.3 billion
Operating profit (prior-year 3 months)
KRW -4.6 billion
Operating profit (year to date)
KRW -15.4 billion
Net income (prior-year 3 months)
KRW -7.0 billion
Net income (year to date)
KRW -23.7 billion

Commentary

AI commentary · Not investment advice

What happened

Hyundai Bio reported its third-quarter results for 2026 on a consolidated basis. Sales for the three months were KRW 461.8 million. That is 16.5% lower than the same three months a year earlier, when sales were KRW 553.1 million.

In the company's terms

Operating profit (profit from the core business) for the three months was a loss of KRW 5.17 billion. A year earlier, the loss for the same period was KRW 4.62 billion. Net income (the final profit after taxes and all other items) for the three months was a loss of KRW 6.84 billion. A year earlier, the loss was KRW 7.00 billion.

What changes for shareholders

For the year to date, from January 1 to September 30, sales were KRW 1.31 billion. The operating loss was KRW 15.37 billion. The net loss was KRW 23.72 billion.

Comments

No comments yet

Comments from shareholders will appear here.